Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
We recently showed that measures of cannabinoid 1 receptor (CB1R) mRNA and protein were significantly reduced in dorsolateral prefrontal cortex (DLPFC) area 9 in schizophrenia subjects relative to matched normal comparison subjects. However, other studies have reported unaltered or higher measures of CB1R levels in schizophrenia. To determine whether these discrepancies reflect differences across brain regions or across subject groups (eg, presence of depression, cannabis exposure, etc), we used immunocytochemical techniques to determine whether lower levels of CB1R immunoreactivity are (1) present in another DLPFC region, area 46, in the same subjects with schizophrenia, (2) present in area 46 in a new cohort of schizophrenia subjects, (3) present in major depressive disorder (MDD) subjects, or (4) attributable to factors other than a diagnosis of schizophrenia, including prior cannabis use. CB1R immunoreactivity levels in area 46 were significantly 19% lower in schizophrenia subjects relative to matched normal comparison subjects, a deficit similar to that observed in area 9 in the same subjects. In a new cohort of subjects, CB1R immunoreactivity levels were significantly 20 and 23% lower in schizophrenia subjects relative to matched comparison and MDD subjects, respectively. The lower levels of CB1R immunoreactivity in schizophrenia subjects were not explained by other factors such as cannabis use, suicide, or pharmacological treatment. In addition, CB1R immunoreactivity levels were not altered in monkeys chronically exposed to haloperidol. Thus, the lower levels of CB1R immunoreactivity may be common in schizophrenia, conserved across DLPFC regions, not present in MDD, and not attributable to other factors, and thus a reflection of the underlying disease process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Self-citationKatona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 2×
“…and undergo nearly identical changes in laminar distribution during postnatal development (Oeth and Lewis, 1993; Eggan et al , 2010); and 3) the antibody utilized in this study exclusively labels symmetric, inhibitory synapses (Katona et al , 1999; Katona et al , 2001; Eggan and Lewis, 2007).”
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121 · cited 1×
“…reflect differences in the cortical regions examined (e.g., DLPFC area 9, anterior cingulate cortex, posterior cingulate cortex, or superior temporal gyrus), or in the presence of co-morbid factors, such as depression, which is present in in ~50% of schizophrenia subjects (Buckley et al , 2009).”
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“…demonstrate that CB1R agonists and endocannabinoid enhancers possess antidepressant-like properties (Bortolato et al , 2007; Mangieri and Piomelli, 2007) and clinical evidence suggests that the CB1R antagonist rimonabant increases the risk of depression and suicidality (Christensen et al , 2007).”
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937 · cited 2×
“…axon terminals contain much higher levels of CB1Rs and are more sensitive to the effects of CB1R agonists than are pyramidal cell axon terminals (Marsicano and Lutz, 1999; Ohno-Shosaku et al , 2002); 2) CB1R-and CCK-containing structures in macaque monkey DLPFC exhibit similar overall…”
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 2×
“Alterations in these neurons might contribute to DLPFCmediated cognitive impairments in schizophrenia, such as working memory dysfunction, through the following mechanism (Elvevag and Goldberg, 2000; Weinberger et al, 2001; Lewis et al, 2005).”
InfluentialELECTRICAL SYNAPSES IN THE MAMMALIAN BRAIN
Connors, B. W., & Long, M. A. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131128 · Cited by 784
Gamma Oscillations Correlate with Working Memory Load in Humans
Howard, M. W. (2003) · Cerebral Cortex · doi:10.1093/cercor/bhg084 · Cited by 766 · cited 1×
“In particular, networks of interconnected GABA interneurons are essential for the synchronization of large ensembles of neurons (Connors and Long, 2004), including gamma band oscillations that increase in the DLPFC with working memory load in humans (Howard et al , 2003).”
Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668 · cited 1×
“…and undergo nearly identical changes in laminar distribution during postnatal development (Oeth and Lewis, 1993; Eggan et al , 2010); and 3) the antibody utilized in this study exclusively labels symmetric, inhibitory synapses (Katona et al , 1999; Katona et al , 2001; Eggan and Lewis, 2007).”
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617 · cited 1×
“…of CB1Rs by exogenous cannabinoids would be expected to further impair GABA neurotransmission in an already compromised system and produce the exacerbation of symptoms, including impaired working memory, frequently seen in individuals with schizophrenia who use cannabis (D’Souza et al , 2005).”
Cited by
Cannabis and adolescent brain development.
Lubman, D. I., Cheetham, A., & Yücel, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.009 · Cited by 360
Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies
Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3846 · Cited by 298
Rethinking schizophrenia in the context of normal neurodevelopment
Catts, V. S., Fung, S. J., Long, L. E., Joshi, D., Vercammen, A., Allen, K. M., Fillman, S. G., Rothmond, D. A., Sinclair, D., Tiwari, Y., et al. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00060 · Cited by 206
Adolescent neurodevelopment and substance use: receptor expression and behavioral consequences
Thorpe, H. H. A., Hamidullah, S., Jenkins, B. W., & Khokhar, J. Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107431 · Cited by 97
Gleason, K. A., Birnbaum, S. G., Shukla, A., & Ghose, S. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.122 · Cited by 77
Metadata
- Authors
- Eggan, S. M., Stoyak, S. R., Verrico, C. D., & Lewis, D. A.
- Venue
- Neuropsychopharmacology
- Published
- 2010-06-16
- Volume
- 35
- Issue
- 10
- Pages
- 2060-2071
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2084940915
- Cited by
- 102
- References
- 14
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder. https://app.cochat.ai/papers/10.1038/npp.2010.75
- The paper
- Eggan, S. M., Stoyak, S. R., Verrico, C. D., & Lewis, D. A. (2010). Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder. Neuropsychopharmacology. https://doi.org/10.1038/npp.2010.75
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.